Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPulmonologyBlue Cross Blue Shield LA Bronchial Valves Coverag…
    Ask Trek AI about this page
    Currentblue cross blue shield - louisianaPolicy MA-227

    Bronchial Valves

    Customize your policy alerts

    Sign up for blue cross blue shield - louisiana Policy MA-227 alerts

    Get alerted when Policy MA-227 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing coverage of bronchial (endobronchial/intrabronchial) valves for treatment of prolonged air leaks and for bronchoscopic lung volume reduction in adults with severe emphysema; applies to products administered or underwritten by the Health Plan.

    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyBronchial Valves
    Policy CodePolicy MA-227
    Change TypeNo material changes
    Effective DateSep 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionObtain prior authorization to confirm member benefits and that medical necessity criteria (including pulmonary function, imaging, and prior pulmonary rehabilitation) are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2FDA-approved indications
    15–45%FEV1 inclusion range
    ≥175%RV threshold
    up to 27%Pneumothorax risk in trials

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    31647–31651
    Listed CPT codes
    74.8%1‑yr patient satisfaction (cohort)

    Coverage Criteria

    Initial therapy — Emphysema (endobronchial valve placement)

    Covered when ALL of the following are met

    Emphysema indication

    • Clinical: Medical history and physical exam consistent with emphysema; highly symptomatic despite optimal medical therapy and maximal pulmonary rehabilitation; nonsmoking >=4 months; BMI <35 kg/m2; able to tolerate procedural sedation
    • Pulmonary function: FEV1 >=15% and <=45% predicted; TLC >=100% predicted; RV >=175% predicted; 6MWD >=100 m and <500 m after supervised pulmonary rehabilitation
    • Imaging and collateral ventilation: High-resolution CT demonstrating hyperinflation/emphysema and intact lobar fissures (>=90% completeness) in target regions; if fissure <90% completeness on quantitative CT, absence of collateral ventilation must be confirmed with Chartis system during bronchoscopy

    Initial therapy — Prolonged bronchopleural air leak

    Covered when ALL of the following are met

    Prolonged air leak indication: Adult patient with prolonged air leak following lobectomy, segmentectomy, or lung volume reduction surgery that is not improving >=5 days after chest tube insertion (or meets HDE definition of prolonged leak)

    Use of the Intrabronchial Valve System is limited to 6 weeks per prolonged air leak

    Covered when evidence and selection criteria met

    Evidence summary and guideline-aligned coverage considerations

    Indication groups: 1) Persistent pulmonary air leaks: evidence includes systematic reviews, case series, and observational studies related to the HDE Intrabronchial Valve (Spiration IBV) device; there are no comparative data with alternatives and the evidence is inadequate to determine improved net health outcome. 2) Severe or advanced emphysema with little or no collateral ventilation: multiple randomized controlled trials demonstrate improvements in lung function, exercise tolerance, and some quality-of-life measures at 6–12 months versus usual care, but confidence is limited by study limitations (lack of blinding, loss to follow-up) and there is an increased risk of serious procedure-related adverse events (including pneumothorax in up to 27% of patients). Decisions should consider guideline recommendations for multidisciplinary team assessment and prior supervised pulmonary rehabilitation before valve therapy.

    Do not flatten trial limitations or adverse event risk; consider guideline-recommended multidisciplinary evaluation and optimization prior to intervention.

    Based on review of the available evidence, the Health Plan considers the use of bronchial valves in all situations not explicitly described as covered to be investigational and not covered. This includes any indication or patient presentation that does not meet the specific criteria listed under the policy's covered indications.

    Established contraindications include: cigarette smoking within the prior 4 months; comorbid cardiac illness that would increase surgical mortality (for example, significant coronary heart disease or heart failure with left ventricular ejection fraction <40%); BMI ≥35 kg/m2; inability to complete a 6–10 week pulmonary rehabilitation program; prior ipsilateral cardiothoracic surgery (including lung transplant, LVRS, or lobectomy); end-stage pulmonary disease as defined by severe resting hypoxemia (PaO2 <45 mmHg), hypercapnia (PaCO2 >60 mmHg), FEV1 <15% predicted, or 6-minute walk distance <100 m; large bullae >30% of either lung; and active pulmonary infection.

    For patients with pulmonary air leaks, the available evidence (systematic reviews, case series, and observational studies related to the Humanitarian Device Exemption for the Spiration IBV Valve) is limited and heterogeneous. There are no comparative data with alternatives, and the evidence is considered inadequate and insufficient to determine an improvement in net health outcome. Because of these evidence gaps, a noncoverage or investigational determination may be made for air-leak indications depending on a full review of clinical context and policy criteria.

    Federal and State law, and applicable contract language (including definitions and any specific contract provisions or exclusions), take precedence over this Medical Policy. These legal and contractual provisions must be considered first when determining eligibility for coverage.

    Use of bronchial valves for indications or patient scenarios other than the specific covered indications outlined in this policy is considered investigational (not medically necessary) and is not covered by the Health Plan.

    The evidence for bronchial valves to treat pulmonary air leaks and for some emphysema subpopulations is limited. Systematic reviews, small series, and uncontrolled cohort studies provide heterogeneous data, and randomized trials have limitations. Overall, the body of evidence is considered insufficient to determine an improvement in net health outcome for these uses, particularly in the absence of comparative data and in light of procedure-related harms described in trials.

    Coding

    FDA product codes mentionedmixed
    OAZFDA product code for Intrabronchial Valve System (Spiration IBV Valve) for prolonged air leaks
    NJKFDA product code referenced for Spiration valve system for emphysema
    Codes used to identify services associated with this policyCPT
    31647Bronchoscopy, transbronchial lung volume procedure (as listed in policy)
    31648Bronchoscopy, transbronchial device placement (as listed in policy)
    31649Bronchoscopy, valve removal or replacement (as listed in policy)
    31651Bronchoscopy, additional airway device placement (as listed in policy)
    HCPCSHCPCS
    No codesNo HCPCS codes listed
    ICD-10 DiagnosisICD-10
    All related diagnosesPolicy references all related ICD-10 diagnoses
    Codes used to identify services associated with this policyCPT
    31647
    31648
    31649
    31651
    HCPCSHCPCS
    No codes
    ICD-10 DiagnosisICD-10
    All related diagnoses
    FEV1 — inclusion range for emphysema
    FEV1 (spirometry range)>=15% and <=45% predicted
    ContextMarked airflow obstruction on spirometry consistent with emphysema as part of inclusion criteria for EBV placement
    Relation to exclusionsFEV1 <15% predicted is listed among contraindications/ end‑stage disease
    TLC — threshold
    TLC (total lung capacity)>=100% predicted
    Clinical role

    Provider Actions & Authorization

    Prior Authorization

    Prior authorization required — verify benefits and medical necessity

    Confirm member benefits and obtain prior authorization before scheduling or performing bronchial valve procedures to verify contract coverage and that the patient meets medical necessity criteria (including pulmonary function, imaging, and rehabilitation status).

    • Benefits must be available in the member's contract/certificate.
    • Prior authorization is used to confirm medical necessity criteria are met (pulmonary function, imaging, rehab status, etc.).
    Prior Authorization

    Prior authorization for bronchoscopic valve procedures — include selection documentation

    Obtain prior authorization for bronchoscopic valve placement and include documentation supporting patient selection (multidisciplinary assessment, prior pulmonary rehabilitation, imaging and physiologic testing). Anticipate use of CPT codes 31647, 31648, 31649, and 31651 to identify these services.

    • Include evidence of multidisciplinary team assessment, prior pulmonary rehabilitation, high-resolution CT demonstrating hyperinflation/emphysema and fissure completeness, and pulmonary function test results.

    Background

    Bronchial valves are one-way endobronchial devices placed bronchoscopically into airways supplying diseased lung regions. They permit air and secretions to exit the target region on exhalation while limiting inspiratory airflow into that region, promoting regional volume reduction and collapse. Valves are used for closure of prolonged bronchopleural air leaks and for bronchoscopic lung volume reduction in selected patients with severe emphysema and little or no collateral ventilation, with candidate selection informed by CT assessment of fissure completeness or physiologic assessment (e.g., the Chartis system).

    Definitions

    Collateral ventilation — definition and clinical relevance
    DefinitionCollateral ventilation are alternate airflow pathways that bypass normal bronchial airways; absence of collateral ventilation is associated with better outcomes after valve placement
    AssessmentMeasured intraoperatively with the Chartis System or inferred from CT-based fissure completeness (>=90% indicates intact fissure)
    Clinical relevancePresence of collateral ventilation between target and ipsilateral lobes reduces effectiveness of endobronchial valves for lung volume reduction
    Prolonged air leak — definition
    DefinitionProlonged air leak: an air leak present on postoperative day 7 is considered prolonged unless only during forced exhalation or cough
    Early treatment consideration
    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyBronchial Valves
    Policy CodePolicy MA-227
    Change TypeNo material changes
    Effective DateSep 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionObtain prior authorization to confirm member benefits and that medical necessity criteria (including pulmonary function, imaging, and prior pulmonary rehabilitation) are met.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions & AuthorizationBackgroundDefinitions
    Lung volume measurements showing air trapping are required to document hyperinflation
    Assessment methodMeasured by lung volume testing (e.g., body plethysmography)
    RV — threshold for hyperinflation
    RV (residual volume)>=175% predicted
    PurposeThreshold used to document air trapping/hyperinflation for EBV candidacy
    Follow-up noteResidual volume after 45 days post-procedure can indicate whether lung volume reduction was achieved
    6MWD — requirement after pulmonary rehab
    6-Minute Walk Distance (6MWD)>=100 m and <500 m after supervised pulmonary rehabilitation
    TimingMeasured following supervised pulmonary rehabilitation as part of inclusion criteria
    Related exclusion6MWD <100 m is listed among contraindications (end‑stage disease)
    Nonsmoking — requirement duration
    Nonsmoking duration>=4 months
    Policy contextNonsmoking for greater than or equal to 4 months is required for EBV candidacy; cigarette smoking within prior 4 months is a contraindication
    DocumentationSmoking status should be documented in clinical record for authorization
    BMI — limit
    Body mass index (BMI) limit<35 kg/m2
    RationaleBMI >=35 kg/m2 is listed as an established contraindication to EBV therapies
    Clinical implicationBMI must be documented as part of eligibility assessment
  1. CPT codes commonly used: 31647, 31648, 31649, 31651.
  2. Prior Authorization

    Prior authorization required for listed codes

    Obtain prior authorization for all listed procedure codes before delivering services; do not perform these services without authorization.

    • NOTICE: All codes listed on the Medical Policy require prior authorization.
    Step Therapy

    Therapy optimization required before valve consideration

    Document that the patient has had optimized medical therapy and maximal pulmonary rehabilitation prior to consideration of endobronchial valve therapy for emphysema.

    • Medical history and exam consistent with emphysema and highly symptomatic despite optimal medical therapy and maximal pulmonary rehabilitation.
    • Evidence of completion of supervised pulmonary rehabilitation prior to consideration.
    Step Therapy

    Optimize noninvasive therapy before intervention

    Consider bronchoscopic interventions only for patients refractory to optimized medical care and after pulmonary rehabilitation, consistent with guideline recommendations for selected patients. Ensure noninvasive optimization has been attempted before valve therapy.

    • GOLD and NICE recommend considering bronchoscopic lung volume reduction only in selected patients refractory to optimized care and after pulmonary rehabilitation.
    • Refer to multidisciplinary evaluation when appropriate.
    Note

    Transition and authorization note

    (See adjacent documentation requirements)

    Documentation Required

    Required clinical documentation for emphysema indication

    Provide all required clinical documentation to support emphysema indication when requesting authorization: history and physical consistent with emphysema, evidence of symptomatic disease despite optimal medical therapy, nonsmoking ≥4 months, BMI <35 kg/m2, pulmonary function tests (FEV1, TLC, RV), 6MWD after supervised pulmonary rehabilitation, high-resolution CT showing hyperinflation/emphysema and fissure completeness, and ability to tolerate procedural sedation.

    • FEV1 ≥15% and ≤45% predicted; TLC ≥100% predicted; RV ≥175% predicted.
    • 6MWD ≥100 m and <500 m after supervised pulmonary rehabilitation; nonsmoking ≥4 months; BMI <35 kg/m2.
    • CT demonstrating intact lobar fissures ≥90% completeness or Chartis confirmation of absent collateral ventilation if fissure <90%.
    Documentation Required

    Documentation required for prolonged air leak indication

    For prolonged bronchopleural air leak authorization, provide documentation demonstrating a postoperative air leak not improving ≥5 days after chest tube insertion (or meeting the HDE definition) and note that Intrabronchial Valve System use is limited to 6 weeks per prolonged air leak.

    • An air leak present on postoperative day 7 is considered prolonged unless only during forced exhalation or cough; consider treatment on day 5 if continuous, present during normal inhalation, or present on normal expiration with subcutaneous emphysema or respiratory compromise.
    • Use of the Intrabronchial Valve System is limited to 6 weeks per prolonged air leak.
    Documentation Required

    Recommended documentation — multidisciplinary assessment for emphysema candidates

    Include recommended documentation of multidisciplinary team assessment for emphysema candidates per NICE guidance: evidence of multidisciplinary evaluation, prior pulmonary rehabilitation, assessment of collateral ventilation, and CT imaging demonstrating emphysema and hyperinflation.

    • NICE recommends patient selection by a multidisciplinary team including chest physician, radiologist, thoracic surgeon, and respiratory nurse.
    • Document prior pulmonary rehabilitation and assessment of collateral ventilation (Chartis or quantitative CT fissure analysis).
    Documentation Required

    Authorization transition — accept prior authorizations for 90-day transfer period

    If a member moves from another health plan, provide documentation of the prior authorization from the previous plan to request that Blue Advantage honor the authorization for the same service during a 90-day transition period; the prior authorization must be provided by the member or provider and the service must be covered under the Blue Advantage benefit.

    • Blue Advantage may honor a prior authorization from the previous health plan for a 90-day transition period if documentation is provided.
    • The services must otherwise be covered under the Blue Advantage plan.
    Prior Authorization

    Benefit and medical necessity — confirm contract coverage and criteria

    Confirm that benefits are available in the member's contract/certificate and that all medical necessity criteria in the policy are met before seeking coverage. Lack of contract benefits or failure to meet medical necessity will preclude coverage.

    • Coverage requires both available benefits and fulfillment of the policy's medical necessity criteria and guidelines.
    Billing Rule

    Coding-related denial risk — use listed CPT codes

    Submit claims using the procedure codes identified for these services; claims may be denied if submitted with codes other than those listed (examples include CPT 31647, 31648, 31649, 31651).

    • Claims may be denied if not submitted with the codes identified for services associated with this policy.
    • Verify coding aligns with listed CPT codes (31647, 31648, 31649, 31651).
    Prior Authorization

    Prior authorization required — all listed codes

    All codes listed in this policy require prior authorization; obtain authorization prior to providing services to ensure appropriate utilization and alignment with clinical guidelines.

    • NOTICE: All codes listed on the Medical Policy require prior authorization.
    An air leak present on day 5 may be considered for treatment if continuous, present during normal inhalation, or present on normal expiration with subcutaneous emphysema or respiratory compromise
    Device limitationUse of the Intrabronchial Valve System is limited to 6 weeks per prolonged air leak (HDE indication)
    Collateral ventilation — alternate entry
    Alternate descriptionA pathway of airflow between lobes that, if present between the target and ipsilateral lobes, reduces the effectiveness of endobronchial valves
    Implication for imagingCT-based assessment of fissure completeness is used to infer collateral ventilation; <90% completeness necessitates Chartis confirmation
    Outcome impactPatients without collateral ventilation are more likely to develop lobar atelectasis and derive benefit from valve placement
    Multidisciplinary team (for patient selection)
    Core membersChest physician, radiologist, thoracic surgeon, and respiratory nurse
    PurposeMultidisciplinary team evaluates candidacy for valve therapy per NICE guidance, including review of imaging, pulmonary rehab status, and collateral ventilation assessment
    RecommendationPatient selection by an experienced multidisciplinary team is recommended prior to EBV placement
    Medically Necessary — policy definition
    Medically Necessary - definitionServices that a provider, exercising prudent clinical judgment, would provide to prevent, evaluate, diagnose, or treat an illness and that are: in accordance with nationally accepted standards of medical practice; clinically appropriate; and not primarily for comfort or convenience
    Standards referencedDetermination based on credible scientific evidence, physician specialty recommendations, and relevant clinical standards
    Coverage implicationServices meeting this definition and the policy's medical necessity criteria may be eligible for coverage if benefits exist under the member's contract
    Investigational — policy definition
    Investigational - definitionA treatment, procedure, drug, device, or biological product is investigational if effectiveness has not been clearly tested and it has not been incorporated into standard medical practice
    Basis for determinationDecisions consider FDA marketing status, need for further studies, and consensus of expert opinion supported by reliable evidence
    Policy consequenceUse of bronchial valves outside specified covered indications is considered investigational and not covered